Spotlighting EGCit Linkers & Enzymatic Conjugation to Enable Stable, High Precision Dual Payload ADCs Against Tumor Resistance
- Leveraging the next‑generation EGCit linker to achieve enhanced plasma stability, reduced off‑target uptake, and rapid intracellular release, ensuring controlled delivery of multiple payloads with minimal systemic toxicity
- Employing microbial transglutaminase–based site‑specific conjugation and modular click‑chemistry assembly to achieve uniform DAR, high homogeneity, and orthogonal installation of distinct payloads without cross‑reactivity
- Advancing dual‑payload ADCs, including the branched‑linker TROP‑2 candidate CBB‑120, to simultaneously target tumor heterogeneity and resistance pathways through synergistic mechanisms of action